(Q33404027)

English

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Lisa M DeAngelis

object named as

Lisa M DeAngelis

5

0 references

object named as

Minesh P Mehta

11

0 references

19

object named as

Patrick Y Wen

1 reference

Europe PubMed Central

26 July 2017

1

object named as

Eudocia Q Lee

1 reference

Europe PubMed Central

26 July 2017

Timothy F. Cloughesy

17

object named as

Timothy F Cloughesy

1 reference

Europe PubMed Central

26 July 2017

10

object named as

Jan Drappatz

1 reference

Europe PubMed Central

26 July 2017

Susan Soon Mee Chang

8

object named as

Susan M Chang

1 reference

Europe PubMed Central

26 July 2017

2

object named as

John Kuhn

1 reference

Europe PubMed Central

26 July 2017

Frank Lieberman

6

object named as

Frank Lieberman

1 reference

Europe PubMed Central

26 July 2017

Michael D Prados

16

object named as

Michael D Prados

1 reference

Europe PubMed Central

26 July 2017

4

object named as

Lauren Abrey

1 reference

Europe PubMed Central

26 July 2017

Kenneth D Aldape

13

object named as

Kenneth Aldape

1 reference

Europe PubMed Central

26 July 2017

author name string

Kathleen R Lamborn

3

1 reference

Europe PubMed Central

26 July 2017

H Ian Robins

7

1 reference

Europe PubMed Central

26 July 2017

W K Alfred Yung

9

1 reference

Europe PubMed Central

26 July 2017

Victor A Levin

12

1 reference

Europe PubMed Central

26 July 2017

Janet E Dancey

14

1 reference

Europe PubMed Central

26 July 2017

John J Wright

15

1 reference

Europe PubMed Central

26 July 2017

Mark R Gilbert

18

1 reference

Europe PubMed Central

26 July 2017

publication date

24 October 2012

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

14

1 reference

Europe PubMed Central

26 July 2017

12

1 reference

Europe PubMed Central

26 July 2017

1511-1518

1 reference

Europe PubMed Central

26 July 2017

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Sorafenib exerts anti-glioma activity in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Malignant gliomas in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Malignant astrocytic glioma: genetics, biology, and paths to treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

21 June 2018

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS264

21 January 2018

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS264

21 January 2018

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS264

21 January 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS264

21 January 2018

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS264

21 January 2018

Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS264

21 January 2018

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS264

21 January 2018

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499017

31 October 2018

Identifiers

10.1093/NEUONC/NOS264

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33404027&oldid=1857584117"